---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-102561"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:35:32.152882+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences receives $9.75M cash + $3.25M Imugene shares from convertible note maturity

## Summary
- Convertible note from August 2023 azer-cel deal with Imugene matured; Precision receives $9.75M cash and $3.25M in Imugene ordinary shares.
- Cash injection extends expected runway into second half of 2026; Q2 2024 cash balance was ~$123.6M before this receipt.
- Company on track to file applications for PBGENE-HBV (chronic hepatitis B) with multiple global regulators later in 2024.
- Precision expects to generate Phase 1 clinical data across multiple in vivo gene editing programs starting first half of 2025.

## SEC filing metadata
- accession: 0000950170-24-102561
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024102561/0000950170-24-102561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024102561/dtil-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-102561
- JSON: https://secwatch.observer/filing/0000950170-24-102561.json
- Plain text: https://secwatch.observer/filing/0000950170-24-102561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.